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ABSTRACT 
Background: Preclinical evidence from lung cancer cell lines and animal models suggest 
that statins could have anticancer properties. We investigated whether statin users had 
reduced risk of cancer-specific mortality in a population based cohort of lung cancer patients. 
Methods:  Newly diagnosed lung cancer patients, from 1998 to 2009, were identified from 
English cancer registry data and linked to the UK Clinical Practice Research Datalink, 
providing prescription records, and to Office of National Statistics mortality data up to 2012. 
Cox regression models were used to calculate hazard ratios (HR) for cancer-specific mortality 
and 95% confidence intervals (CIs) by statin use before and after diagnosis and to adjust 
these HRs for potential confounders. 
Results: In 3,638 lung cancer patients, there was some evidence that statin use after diagnosis 
was associated with reduced lung cancer-specific mortality (adjusted HR=0.89, 95% CI 0.78, 
1.02; P=0.09). Associations were more marked after 12 prescriptions (adjusted  HR=0.81, 
95% CI 0.67, 0.98; P=0.03) and when lipophilic statins were investigated (adjusted HR=0.81, 
95% CI 0.70, 0.94; P=0.01) but were attenuated in some sensitivity analyses. Furthermore, in 
11,051 lung cancer patients, statin use before diagnosis was associated with reduced lung 
cancer-specific mortality (adjusted HR=0.88, 95% CI, 0.83, 0.93; P<0.001). 
Conclusions: There was some evidence that lung cancer patients who used statins, and 
particularly simvastatin, had reduced rates of cancer-specific mortality.  
Impact: These findings should first be confirmed in observational studies, but provide some 
support for conducting randomized controlled trials of simvastatin as adjuvant cancer therapy 
in lung cancer patients. 
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Introduction 
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are primarily used for 
primary and secondary prevention of coronary heart disease.(1) In recent decades the 
potential anticancer properties of statins have received much attention.(2-4)  Preclinical 
studies have proposed a number of relevant biological mechanisms including inhibition of 
cell proliferation, stimulation of anticancer immune surveillance, and interruption of 
oncogenic signalling.(2) In humans, epidemiological studies have shown reductions in cancer 
recurrence or cancer-specific mortality at a number of cancer sites including breast(5), 
prostate(6) and colorectal.(7) 
 
The preclinical evidence for the effect of statins on lung cancer appears promising. In vitro 
studies have shown reduced proliferation(8, 9), reduced migration(10) and increased 
apoptosis(9) in lung cancer cell lines treated with simvastatin and an in vivo study,(10) using 
a mouse model, demonstrated reduced tumour growth and bone metastases after simvastatin 
treatment. Despite this preclinical evidence, few studies in humans have investigated the 
association between statin use and survival in lung cancer patients. A recent Danish study(11) 
observed some evidence of a weak reduction in cancer-specific mortality in individuals who 
used statins before lung cancer diagnosis (HR=0.87 95% CI 0.83, 0.92). However, this study 
did not report findings for statins used after diagnosis, the time period when clinical 
intervention is possible, nor did it report results for lung cancer by statin type or evidence of 
dose response associations. A phase 3 randomised clinical trial has also been conducted in 
846 small cell lung cancer patients which compared chemotherapy and pravastatin to 
chemotherapy alone.(12) Although the final trial report has not yet been published, the results 
were presented at the World Conference on Lung Cancer, Sydney, and a significant 
protective effect was not observed.(13) It is worth noting that this trial only investigated 
pravastatin and included only patients with small cell lung cancer. Consequently, there 
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remains a need to investigate the association between statin use and survival after lung cancer 
diagnosis, particularly for simvastatin because of the considerable supportive preclinical 
evidence. 
   
Therefore, we investigated the effect of statin use, both before and after cancer diagnosis, on 
cancer-specific mortality in a large population-based cohort of lung cancer patients.  
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Materials and Methods 
Data source 
This study is based upon linkages between the National Cancer Data Repository (NCDR), the 
UK Clinical Practice Research Datalink (CPRD) and the Office of National Statistics (ONS) 
death registration data. NCDR data, available for England, included all patients identified by 
cancer registries, containing date and site of primary cancer diagnosis, and treatment data. 
The CPRD includes general practice records and contains demographic information, clinical 
diagnoses, and prescription data of documented high quality(14-16). CPRD is the world’s 
largest computerized database of longitudinal patient records comprising approximately 7% 
of the UK population. ONS death registration data provided date and cause of death. 
Linkages between data sources were conducted using a deterministic algorithm based upon 
NHS number, gender, date of birth, and postcode. Ethical approval for all observational 
research using CPRD data has been obtained from a multicentre research ethics committee.
  
Cohort selection 
A cohort of newly diagnosed lung cancer patients was identified from cancer registry 
recorded primary diagnosis of lung cancer (ICD code C34 Malignant neoplasm of bronchus 
and lung) between 1998 and 2009, from NCDR. Cohort members with previous NCDR 
cancer diagnosis, apart from in situ neoplasms and non-melanoma skin cancers, were 
excluded. This cohort was linked to CPRD and ONS death registration data. Deaths were 
identified from ONS with coverage up to January 2012 with lung cancer-specific deaths 
defined as those with underlying cause of death ICD code C34.  
 
Exposure data  
Statins were determined from GP prescribing records (from CPRD) based upon the Statins 
section of the British National Formulary (Section 2.12).(17) A quantity of 28 tablets (the 
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most common pack size prescribed) was assumed for approximately 1% of prescriptions 
where quantity was missing or assumed incorrect. The daily defined doses (DDD) in each 
prescription were calculated by multiplying the quantity by the strength (in mg) and dividing 
by the mg in a DDD from the World Health Organisation.(18)  In the main analysis of stains 
after diagnosis, the exposure window for statin use was from lung cancer diagnosis to death 
or end of follow-up, but was subject to a lag (described later).  In the main analysis of statins 
before diagnosis the exposure window was from one year prior to lung cancer diagnosis to 
the date of lung cancer diagnosis.  Statins were analysed individually and grouped by type 
into liphophilic statins (including simvastatin, fluvastatin and cerivastatin) and hydrophilic 
statins (including atorvastatin, pravastatin and rosuvastatin). 
 
Covariates 
Data available from NCDR included histology, surgery, chemotherapy and radiotherapy in 
the six months after diagnosis. Cancer registry recorded histology codes (International 
Classification of Diseases for Oncology, 3rd edition) were used to identify small cell lung 
cancer patients. Smoking, alcohol, and body mass index (BMI) were determined from the 
closest GP record prior to lung cancer diagnosis (values more than ten years prior to 
diagnosis were ignored). Comorbidities were determined prior to diagnosis from GP 
diagnosis codes using comorbidities comprising a recent adaptation of the Charlson 
index.(19) CPRD provided deprivation based upon postcode of residence using the 2004 
index of multiple deprivation for England.(20) Low-dose aspirin, beta-blocker use and 
bisphosphonate use were determined from GP prescription records to allow for adjustment, 
because of potential associations with cancer-specific mortality.  
 
Statistical analysis 
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In analyses of statin use after lung cancer diagnosis, deaths in the first year after diagnosis 
were removed as it seemed unlikely that statin use after diagnosis could influence such 
deaths. Consequently, patients were followed from one year after lung cancer diagnosis to 
death, end of registration with the general practice, last date of data collection from general 
practice or end of ONS follow-up. Time-dependent Cox regression models were used to 
calculate hazard ratios for lung cancer-specific death (HRs) and 95% confidence intervals 
(95% CIs). Statin use was defined as a time varying covariate(21) with patients initially 
considered non-users and then users after a lag of 6 months after their first statin prescription. 
A lag is recommended(22) and was used to remove prescriptions in the 6 months prior to 
death as these may reflect increased contact with medical professionals or end of life care. In 
sensitivity analyses the duration of this lag was varied. Dose-response analyses were 
conducted with individuals considered non-users prior to 6 months after first use, a short term 
user between 6 months after first use and 6 months after the 12th prescription (or 365th DDD) 
and a longer term user after this time. Adjusted analyses were conducted by including 
potential confounders in the cox regression models. Analyses were conducted by number of 
prescriptions, number of DDDs and type of statin and repeated for all-cause mortality (which 
does not require classification of the cause of death). Subgroup analyses were conducted by 
gender, type of lung cancer (i.e. small cell versus non-small cell) and pre-diagnostic statin 
use. Tests for interactions were performed using interaction terms within the Cox regression 
models. Sensitivity analyses were conducted increasing the lag to 1 year, additionally 
adjusting for smoking, BMI, bisphosphonate use and lung cancer type. A simplified analysis 
was conducted comparing statin users to non-users in the first year after lung cancer 
diagnosis in individuals alive 1 year after diagnosis, thus controlling for immortal time 
bias(23) without requiring time varying covariates. A nested case-control analysis of the 
cohort was also conducted in which cases who died due to lung cancer were matched on 
gender, age (in 5 years) and year of diagnosis (in 2 years) to five risk-set controls who lived 
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at least as long after their lung cancer diagnosis. The exposure period was from lung cancer 
diagnosis until 6 months prior to lung cancer-specific death in cases and for a period of 
identical duration from diagnosis in matched controls. Conditional logistic regression was 
then used to calculate corresponding odds ratios (ORs), and 95% confidence intervals (CIs), 
for statin use in the exposure period adjusting for potential confounders. 
 
In analyses of statin use before cancer diagnosis, lung cancer patients were followed from 
diagnosis to death or censoring (as defined previously). Deaths in the first year after 
diagnosis were not excluded. Cox regression models were used to calculate HRs and 95% CIs 
for stain use based upon prescriptions in the year prior to diagnosis (restricted to individuals 
with at least 1 year of records prior to diagnosis). Adjusted analysis were conducted including 
only potential confounders recorded prior to diagnosis to avoid over-adjustment (such as age, 
year, gender, comorbidities, deprivation, aspirin and beta-blocker user in the year prior to 
diagnosis).(24, 25) Analyses were conducted by statin type, number of prescriptions and 
number of DDDs. Subgroup analyses were conducted by gender. Sensitivity analyses were 
conducted additionally adjusting for BMI, bisphosphonate use and smoking prior to diagnosis 
and defining statin use as a prescription from 2 years to 6 months prior to diagnosis 
(restricted to individuals with at least 2 years of records prior to diagnosis).  
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Results 
Patient cohort  
A total of 14,689 lung cancer patients were diagnosed in NCDR with linked CPRD data. The 
analysis of statin use after lung cancer contained 3,638 patients, because 11,051 were 
excluded with less than 1 year of follow-up (10,265 of whom had died), with average follow-
up of 3 years (maximum 14 years). The analysis of statin use before lung cancer contained 
13,398 patients, because 1,291 were excluded with less than 1 year of records before 
diagnosis, with average follow-up of 1 year (maximum 14 years). 
 
Patient characteristics by statin use are shown in Table 1. Statin users (before or after 
diagnosis) were more likely to be diagnosed more recently, be older, be male, have higher 
BMI, have comorbidities (particularly for cerebrovascular disease, diabetes and myocardial 
infarction) and to use aspirin and beta-blockers.  Statin users after diagnosis were less likely 
to have chemotherapy. The associations between statin use and other patient characteristics 
were less marked.  In 3,357 lung cancer patients who lived at least 1 year after diagnosis and 
who had 1 year of records before diagnosis, 2,223 did not use statins in the year before 
diagnosis and did not use statins any time after diagnosis, 76 used before but not after, 256 
used after but not before and 802 used before and after. 
 
Statin use after diagnosis  
Overall, statin users after diagnosis had an 11% reduction in the rate of lung cancer-specific 
mortality (adjusted HR=0.89, 95% CI 0.78, 1.02; P=0.09) compared with statin non-users 
after adjustment for confounders, Table 2. Compared with statin non-users, individuals with 1 
to 12 statin prescriptions after diagnosis had a 6% reduction (adjusted HR=0.94, 95% CI 
0.81, 1.09; P=0.39) whilst individuals with more than 12 prescriptions had a 19% reduction 
(adjusted HR=0.81, 95% CI 0.67, 0.98; P=0.03) in the rate of lung cancer-specific mortality.  
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A similar pattern was seen for statin use based upon DDDs.  There was some indication that 
lipophilic statins (adjusted HR=0.81, 95% CI 0.70, 0.94; P=0.01), particularly simvastatin 
(adjusted HR=0.80, 95% CI 0.69, 0.93; P=0.003), appeared to have more protective 
associations than hydrophilic agents (adjusted HR=1.00, 95% CI 0.85, 1.18; P=0.01). Similar 
associations were observed for all-cause mortality. In subgroup analyses (Table 3) there were 
no marked differences in associations by gender (P for interaction=0.47), pre-diagnostic 
statin use (P for interaction=0.49) or by lung cancer type (P for interaction=0.12). The 
associations were little altered in most sensitivity analyses but they were attenuated when the 
lag was increased to 1 year (adjusted HR=0.92, 95% CI 0.80, 1.05; P=0.22) 
 
Statin use before diagnosis 
Overall, statin users before diagnosis had a 12% reduction in rate of lung cancer-specific 
mortality (adjusted HR=0.88, 95% CI 0.83, 0.93; P<0.001) compared with statin non-users 
following adjustment for confounders, Table 4. The magnitude of the reduction in risk of 
lung cancer-specific death was similar in patients with 1 to 12 statin prescriptions in the year 
before diagnosis (adjusted HR=0.87, 95% CI 0.82, 0.92; P<0.001) and in those with more 
than 12 prescriptions  (adjusted HR=0.91, 95% CI 0.84,0.99; P=0.02) compared with statin 
non-users. Comparable associations were observed for all-cause mortality. The observed 
associations were similar by statin type, by gender (P for interaction=0.10) and in sensitivity 
analyses, Table 5. 
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Discussion 
In this large population-based cohort, lung cancer patients who used statins after diagnosis 
had a non-significant 11% reduction in cancer-specific mortality and those who used 
simvastatin had a 20% reduction in cancer-specific mortality. These association were 
apparent when prescriptions in the 6 months prior to death, which could reflect end of life 
care, were removed but were attenuated in a sensitivity analysis which removed prescriptions 
in the year prior to death. Lung cancer patients who used statins in the year before diagnosis 
had a 12% reduction in cancer-specific mortality. This association was little altered in 
sensitivity analyses.  
 
Although there have not been any epidemiological studies which have investigated the 
association between statin use after lung cancer diagnosis and cancer-specific mortality, a 
recent trial(12, 13) found no protective effect of pravastatin and chemotherapy compared to 
chemotherapy alone in small cell lung cancer patients. Our study also found no association 
between pravastatin use after diagnosis and cancer specific mortality (adjusted HR=1.23 95% 
CI 0.85, 1.77; P=0.27), but we found some evidence of protective associations for other 
statins which were not investigated in this trial, such as simvastatin. A similar phase 2 
trial(26) has also been conducted which included 106 advanced (stage 3b or 4) non-small cell 
lung cancer patients. This trial observed a weak improvement in survival in a group that 
received simvastatin plus gefitinib compared with gefitinib only (HR=0.88 95% CI 0.57, 
1.35: P=0.49), but this was not significant. We observed a slightly more marked, but not 
inconsistent, inverse association between simvastatin and cancer-specific mortality (adjusted 
HR=0.80 95% CI 0.69, 0.93; P=0.003). Other early phase trials, though not powered to report 
upon efficacy, are also in progress(27-30) but contain relatively small numbers. 
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Statin use before diagnosis and survival of lung cancer patients was investigated in a 
subgroup of a large Danish epidemiological study.(11)  This Danish study demonstrated a 
weak protective effect of pre-diagnostic statins on cancer-specific mortality in lung cancer 
patients (adjusted HR=0.87 95% CI 0.83, 0.92) almost identical to our finding (adjusted 
HR=0.88 95% CI 0.83, 0.93), but this study did not report results for different types of statins 
or dose response analyses in lung cancer patients.  
 
Our study has several strengths and limitations. This is the first study to investigate statin use 
after diagnosis and lung cancer-specific mortality. The cohort was large with long follow-up 
of up to 14 years. NCDR and ONS data allowed robust verification of cancer diagnosis and 
death. Although some misclassification of cause of death is possible, this seems unlikely to 
bias results particularly as analysis of all-cause mortality produced similar findings. Routinely 
recorded GP dates of prescriptions were used eliminating the potential for recall bias.  
However, misclassification of statin use is possible due to over the counter use, but only low 
dose 10mg simvastatin is available over the counter in the UK and only from 2004.(31)  Non-
compliance may also contribute to misclassification, but associations were also apparent in 
patients who had 12 or more statin prescriptions in whom non-compliance is of less concern. 
Furthermore, any misclassification of statin usage is likely to drag associations to the null rather 
than create spurious associations.  
 
The cause of any reduction in lung cancer-specific mortality in lung cancer patients using 
statins is unknown. As with all observational studies, it is not possible to rule out residual 
confounding by unrecorded or incomplete variables. In particular adjustments for stage were 
not possible which could influence results for statins after diagnosis but such adjustments are 
probably not appropriate for the analysis of statins before diagnosis, as stage may lie on the 
causal pathway. The observed associations could also be influenced by confounding by 
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indication(32) or the healthy user effect,(33) though these biases would assume that statin 
users were healthier but in our cohort statin users had higher BMI and more comorbidities.  
The observed associations are consistent with the pre-clinical evidence for anti-cancer 
properties of statins from lung cancer cell lines(8-10) and mouse models.(10) These results 
require confirmation in further large epidemiological studies, particularly those with 
complete stage data, which could inform the decision to conduct a trial of simvastatin in lung 
cancer patients. 
 
In conclusion, in this large population-based lung cancer cohort, there were weak inverse 
associations between statin usage and time to cancer-specific death. These associations could 
be causal or could reflect residual confounding or other biases. 
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Table 1. Characteristics of lung cancer patients by statin use before and after diagnosis. 
Characteristics 
Statin use in year 
prior to  diagnosisa  
Statin use in year after 
diagnosisb  
Statin use after 
diagnosisb 
Ever n (%) Never (%) User n (%) Non-user (%) User n (%) Non-user (%) 
 [n=13,398] [n=3,638] [n=3,638] 
 Year of diagnosis: 1998-2000 102 (3) 2,204 (22)  24 (3) 618 (22)  79 (7) 563 (22) 
                                2001-2003 451 (14) 2,893 (29) 132 (15) 754 (27) 217 (19) 669 (26) 
                                2004-2006  1,118 (34) 2,650 (26) 279 (32) 690 (25) 347 (31) 622 (25) 
                                2007-2009 1,616 (49) 2,362 (23) 428 (50) 713 (26) 472 (42) 669 (27) 
       
Age at diagnosis: < 50  16 (0) 405 (4) 7 (1) 166 (6) 14 (1) 159 (6) 
                             50-59 230 (7) 1,363 (13) 84 (10) 486 (18) 132 (12) 438 (17) 
                             60-69 966 (29) 2,607 (26) 295 (34) 873 (31) 377 (34) 791 (31) 
                             70-79 1,447 (44) 3,447 (34) 360 (42) 897 (32) 451 (40) 806 (32) 
                             80-89 598 (18) 2,045 (20) 115 (13) 325 (12) 137 (12) 303 (12) 
                             ≥ 90 30 (1) 242 (2) 2 (0) 28 (1) 4 (0) 26 (1) 
       
Gender: Males 2,030 (62) 5,886 (58) 541 (63) 1,563 (56) 690 (62) 1,414 (56) 
       
Treatment within 6 months of cancer diagnosis      
  Surgeryc 339 (13) 883 (11) 212 (31) 659 (31) 333 (38) 538 (28) 
  Chemotherapy 743 (23) 2,287 (23) 267 (31) 993 (36) 324 (29) 936 (37) 
  Radiotherapy 1,028 (31) 3,197 (32) 319 (37) 1,062 (38) 377 (34) 1,004 (40) 
       
Histology: Non-small cell 1,901 (58) 5,627 (56) 638 (74) 1,982 (71) 835 (75) 1,785 (71) 
                  Small cell 418 (13) 1,257 (12) 89 (10) 335 (12) 108 (10) 316 (13) 
                  Missing 968 (29) 3,225 (32) 136 (16) 458 (17) 172 (15) 422 (17) 
       
Smoking status prior to cancer diagnosis      
  Non-smoker 372 (11) 1,338 (13) 100 (12) 385 (14) 128 (11) 357 (14) 
  Ex-smoker 1,688 (51) 3,175 (31) 439 (51) 955 (34) 525 (47) 869 (34) 
  Current smoker 1,149 (35) 4,305 (43) 295 (34) 1,144 (41) 411 (37) 1,024 (41) 
  Missing 78 (2) 1,291 (13) 29 (3) 291 (10) 51 (5) 269 (11) 
       
Alcohol consumption prior to diagnosis       
  Never 564 (17) 1,271 (13) 132 (15) 340 (12) 165 (15) 307 (12) 
  Ever 2,175 (66) 5,709 (56) 586 (68) 1,671 (60) 750 (67) 1,507 (60) 
  Missing 548 (17) 3,129 (31) 145 (17) 764 (28) 200 (18) 709 (28) 
       
BMI (kg/m2) prior to diagnosis: mean (sd)  26.4 (5.0) 24.8 (4.8) 26.8 (4.9) 25.2 (4.7) 26.6 (4.9) 25.1 (4.7) 
  Underweight (<18.5) 119 (4) 510 (5) 23 (3) 109 (4) 29 (3) 103 (4) 
  Normal (18.5 to 25)  1,074 (33) 3,451 (34) 257 (30) 980 (35) 336 (30) 901 (36) 
  Overweight (25-30) 1,124 (34) 2,244 (22) 296 (34) 722 (26) 378 (34) 640 (25) 
  Obese (>30) 598 (18) 946 (9 175 (20) 299 (11) 214 (19) 260 (10) 
  Missing 372 (11) 2,958 (27) 112 (13) 665 (24) 158 (14) 619 (25) 
       
Deprivation fifth: 1st (least deprived) 552 (17) 1,786 (17) 154 (18) 536 (19) 201 (18) 489 (19) 
                             2nd 638 (19) 1,945 (25) 160 (19) 527 (19) 204 (18) 483 (19) 
                             3rd  648 (20) 2,080 (21) 166 (19) 557 (20) 213 (19) 510 (20) 
                             4th  712 (22) 2,194 (22) 185 (21) 621 (22) 243 (22) 563 (22) 
                             5th (most deprived) 725 (22) 2,070 (20) 195 (23) 528 (19) 251 (23) 472 (19) 
                             Missing 12 (0) 33 (0) 3 (0) 6 (0) 3 (0) 6 (0) 
       
Comorbidity prior to cancer diagnosis       
  Cerebrovascular disease 552 (17) 697 (7) 106 (12) 140 (5) 125 (11) 121 (5) 
  Chronic pulmonary disease  871 (27) 2,517 (25) 226 (26) 703 (25) 296 (27) 633 (25) 
  Congestive heart disease 307 (9) 593 (6) 64 (7) 98 (4) 72 (6) 90 (4) 
  Diabetes 854 (12) 600 (6) 203 (24) 132 (5) 230 (21) 105 (4) 
  Myocardial infarction 817 (25) 368 (4) 186 (22) 106 (4) 210 (19) 82 (3) 
  Peptic ulcer disease 263 (8) 743 (7) 58 (7) 188 (7) 79 (7) 167 (7) 
  Peripheral vascular disease 695 (21) 677 (7) 173 (20) 161 (6) 194 (17) 140 (6) 
  Renal disease 480 (15) 358 (4) 98 (11) 99 (4) 111 (10) 86 (3) 
       
Other medication use after diagnosis       
  Low dose aspirin used  2,109 (64) 1,770 (18) 550 (64) 620 (22) 710 (64) 460 (18) 
  Beta-blocker used  1,050 (32) 1090 (11) 310 (36) 378 (14) 407 (37) 281 (11) 
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a Analysis includes lung cancer patients who have more than 1 year of records prior to diagnosis. b Analysis 
includes lung cancer patients who live more than 1 year after diagnosis. c Excluding cancer patients from Thames 
Registry as surgery information not available. d Low dose aspirin and beta-blocker use ever after diagnosis for 
statin use after diagnosis columns, low dose aspirin and beta-blocker use in year prior to diagnosis for statin use 
in year prior to diagnosis column. 
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Table 2. Association between statin usage after cancer diagnosis and cancer-specific and all-cause mortality in lung cancer patients. 
Medication usage after diagnosis 
Cancer-
specific 
mortality 
All-
cause 
mortality
All 
patients
Person 
years 
Cancer-specific mortality  All-cause mortality 
Unadjusted 
HR (95%CI) P 
Adjusteda
HR (95%CI) P 
Unadjusted 
HR (95%CI) P 
Adjusteda 
HR (95%CI) P 
Number of patients     [n=3,638]  [n=2,792]  [n=3,638]  [n=2,792]  
             
Statin non-user 1,669 1,962 2,523 4,619  1.00  1.00  1.00  1.00  
Statin user b 556 700 1,115 2,135 0.84 (0.76, 0.92) <0.001 0.89 (0.78, 1.02) 0.09 0.89 (0.82, 0.97) 0.01 0.91 (0.80, 1.02) 0.10 
             
Statin user 1 to 11 prescriptions c 355 422 535 977 0.84 (0.75, 0.94) 0.003 0.94 (0.81, 1.09) 0.39 0.88 (0.79, 0.98) 0.02 0.95 (0.83, 1.09) 0.44 
Statin user  ≥ 12 prescriptions c 201 278 580 1,158 0.84 (0.72, 0.97) 0.02 0.81 (0.67, 0.98) 0.03 0.91 (0.80, 1.04) 0.17 0.84 (0.71, 0.99) 0.04 
             
Statin user 1 to 365 ddds c 337 406 493 903 0.90 (0.80, 1.01) 0.07 0.94 (0.81, 1.09) 0.40 0.95 (0.85, 1.06) 0.34 0.96 (0.84, 1.10) 0.57 
Statin user  ≥ 365 ddds c 219 294 622 1,232 0.76 (0.66, 0.88) <0.001 0.82 (0.68, 0.98) 0.03 0.82 (0.72, 0.93) 0.002 0.83 (0.70, 0.97) 0.02 
             
Simvastatin non-user  1,912 2,227 2,867 5,210  1.00  1.00  1.00  1.00  
Simvastatin user b 343 435 771 1,544 0.77 (0.68, 0.86) <0.001 0.80 (0.69, 0.93) 0.003 0.80 (0.72, 0.89) <0.001 0.81 (0.71, 0.92) 0.001 
             
Simvastatin 1 to 11 prescriptions c 220 268 387 777 0.75 (0.65, 0.86) <0.001 0.82 (0.69, 0.98) 0.03 0.78 (0.69, 0.89) <0.001 0.84 (0.72, 0.98) 0.03 
Simvastatin  ≥ 12 prescriptions c 123 167 384 767 0.80 (0.67, 0.97) 0.02 0.76 (0.60, 0.95) 0.01 0.84 (0.72, 0.99) 0.04 0.75 (0.62, 0.91) 0.004 
             
Atorvastatin non-user  2,083 2,432 3,301 6,126  1.00  1.00  1.00  1.00  
Atorvastatin user b 172 230 337 628 0.93 (0.80, 1.09) 0.37 0.93 (0.78, 1.12) 0.47 1.04 (0.91, 1.20) 0.52 1.03 (0.88, 1.21) 0.68 
             
Pravastatin non-user  2,216 2,615 3,564 6,620  1.00  1.00  1.00  1.00  
Pravastatin user b 39 47 74 133 1.02 (0.74, 1.39) 0.93 1.23 (0.85, 1.77) 0.27 1.01 (0.76, 1.35) 0.94 1.11 (0.79, 1.56) 0.53 
             
Rosuvastatin non-user 2,237 2,640 3,598 6,668  1.00  1.00  1.00  1.00  
Rosuvastatin user b 18 22 40 86 0.93 (0.58, 1.47) 0.74 1.15 (0.66, 2.01) 0.61 0.89 (0.58, 1.35) 0.58 0.87 (0.51, 1.48) 0.61 
             
Fluvastatin non-user 2,246 2,651 3,624 6,726  1.00  1.00  1.00  1.00  
Fluvastatin user b 9 11 14 28 1.16 (0.60, 2.23) 0.66 0.98 (0.47, 2.09) 0.98 1.17 (0.65, 2.12) 0.60 1.07 (0.55, 2.06) 0.85 
             
Any lipophilicd non-user 1,901 2,214 2,851 1,573  1.00  1.00  1.00  1.00  
Any lipophilic statin user b 354 448 787 5,181 0.78 (0.69, 0.87) <0.001 0.81 (0.70, 0.94) 0.01 0.81 (0.73, 0.90) <0.001 0.82 (0.72, 0.93) 0.002 
             
Any hydrophilicd non-user 2,027 2,367 3,205 5,945  1.00  1.00  1,00  1.00  
Any hydrophilic statin user b 228 295 433 809 0.96 (0.84, 1.10) 0.54 1.00 (0.85, 1.18) 0.97 1.04 (0.92, 1.17) 0.54 1.05 (0.91, 1.22) 0.49 
a Adjusted for year of diagnosis, age at diagnosis, gender, radiotherapy within 6 months, chemotherapy within 6 months, surgery within 6 months, comorbidities (prior to diagnosis, including 
cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (after 
diagnosis, as time varying covariates, specifically low dose aspirin and beta-blockers) and deprivation (in fifths). 
b Medication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage and a user after this time, excludes deaths in the year after 
cancer diagnosis. 
c Medication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage, a user of 0 to 12 prescriptions from 6 months after first 
prescription to 6 months after 12th prescription (or 365th DDD) and a greater user after this time, excludes deaths in the year after cancer diagnosis. 
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d Lipohphilic statins include simvastatin, fluvastatin, cerivastatin; hydrophilic statins include atorvastatin, pravastatin and rosuvastatin. 
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Table 3. Sensitivity analyses for association between statin use and cancer-specific mortality in lung cancer patients. 
 
Cancer-
specific 
mortality
All 
patients 
Person 
years 
User versus non-user  1-11 prescriptions v. none  ≥  12 prescriptions v. none 
Adj HRa (95% CI) P Adj HRa (95% CI) P Adj HRa (95% CI) P 
Main analysis: Statin user versus non-user after diagnosis  1,735 2,792 5,227 0.89 (0.78, 1.02) 0.09 0.94 (0.81, 1.09) 0.39 0.81 (0.67, 0.98) 0.03 
Sub group analyses: Statin user versus non-user after diagnosis, restricted to:        
  Males 1,007 1,620 2,928 0.94 (0.79, 1.12) 0.62 0.99 (0.82, 1.21) 0.96 0.85 (0.66, 1.09) 0.19 
  Females 728 1,172 2,299 0.83 (0.67, 1.03) 0.09 0.86 (0.68, 1.10) 0.23 0.78 (0.58, 1.06) 0.11 
  Pre-diagnosis statin non-users b 1,222 1,912 3,691 0.78 (0.60, 1.02) 0.07 0.64 (0.45, 0.91) 0.01 1.06 (0.72, 1.57) 0.77 
  Pre-diagnosis statin users b 402 697 1,132 0.76 (0.54, 1.07) 0.12 0.83 (0.59, 1.17) 0.29 0.63 (0.42, 0.93) 0.02 
  Small cell lung cancer 268 338 489 0.66 (0.44, 0.99) 0.05 0.64 (0.41, 0.99) 0.05 0.74 (0.41, 1.36) 0.33 
  Non-small cell lung cancer 1,163 1,995 4,090 0.93 (0.79, 1.09) 0.38 1.01 (0.84, 1.21) 0.90 0.80 (0.64, 1.01) 0.06 
Sensitivity analyses: Statin user versus non-user after diagnosis       
  Increasing lag to 1 year 1,735 2,792 5,227 0.92 (0.80, 1.05) 0.23 0.92 (0.80, 1.07) 0.30 0.90 (0.72, 1.14) 0.39 
  Increasing lag to 1 years (simvastatin only) 1,735 2,792 5,227 0.86 (0.74, 1.00) 0.06 0.84 (0.71, 1.00) 0.05 0.91 (0.70, 1.19) 0.50 
  Additionally adjusting for smoking prior to diagnosis  1,584 2,564 4,760 0.90 (0.78, 1.03) 0.12 0.95 (0.82, 1.11) 0.52 0.82 (0.66, 0.97) 0.03 
  Additionally adjusting for BMI prior to diagnosis  1,340 2,206 4,154 0.93 (0.80, 1.08) 0.34 0.98 (0.83, 1.15) 0.80 0.85 (0.68, 1.04) 0.12 
  Additionally adjusting for small cell/non-small cell  1,431 2,333 4,579 0.86 (0.75, 1.00) 0.05 0.92 (0.78, 1.09) 0.32 0.77 (0.62, 0.95) 0.02 
  Additionally adjusting for bisphosphonate usec  1,735 2,792 5,227 0.89 (0.78, 1.02) 0.09 0.94 (0.81, 1.09) 0.40 0.81 (0.67, 0.98) 0.03 
  Based upon first year after diagnosis d 1,735 2,792 5,227 0.90 (0.78, 1.03) 0.13 0.97 (0.83, 1.12) 0.66 0.75 (0.60, 0.93) 0.01 
  Nested case-control analysis e 1,705   0.92 (0.79, 1.07) 0.27 0.98 (0.82, 1.15) 0.77 0.81 (0.65, 1.01) 0.06 
a Except where otherwise stated, all analyses of post-diagnostic statin use adjusted for year of diagnosis, age at diagnosis, gender, surgery within 6 months of diagnosis, radiotherapy within 6 months, 
chemotherapy within 6 months, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer 
disease, peripheral vascular disease, renal disease), other medication use (after diagnosis, as time varying covariates, specifically low dose aspirin and beta-blockers) and deprivation (in fifths). 
b Based upon statin use in the year prior to diagnosis, restricted to individuals with 1 year of records prior to lung cancer diagnosis. 
c Contains all confounders in a  along with bisphosphonate use after diagnosis (as a time varying covariate).  
d Simplified analysis, not requiring time varying covariate use, comparing statin users to statin non-users in the first year after diagnosis in individuals living more than 1 year after cancer diagnosis, 
adjusted for all confounders in a but other medication use also restricted to first year after diagnosis. 
e Estimate and 95%CIs are for adjusted OR, 25% (433/1705) of cancer-specific deaths used statins compared with 29% (2388/8150) of risk-set controls (not dying from cancer), matched on age at 
diagnosis, year of diagnosis, gender and adjusted for  all other confounders in a. 
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Table 4. Association between statin usage in the year prior to diagnosis and cancer-specific death in lung cancer patients. 
Medication usage in year  
prior to diagnosis 
Cancer-
specific 
mortality 
All-
cause 
mortality
All 
patients
Person 
years 
Cancer-specific mortality  All-cause mortality 
Unadjusted HR 
(95%CI) P 
Adjusteda HR 
(95%CI) P 
Unadjusted HR 
(95%CI) P 
Adjusteda HR 
(95%CI) P 
Number of patients     [n=13,398]  [n=13,353]  [n=13,398]  [n=13,353]  
             
Statin non-user 8,064 8,926 10,111 9430  1.00   1.00    1.00  1.00  
Statin user  2,558 2,898 3,287 3,077 0.94 (0.90, 0.98) 0.007 0.88 (0.83, 0.93) <0.001 0.97 (0.93, 1.01) 0.10 0.89 (0.85, 0.94) <0.001 
             
Statin user 1 to 11 prescriptions  1780 2,011 2,290 2,235 0.92 (0.87, 0.96) 0.001 0.87 (0.82, 0.92) <0.001 0.94 (0.89, 0.98) 0.01 0.88 (0.83, 0.93) <0.001 
Statin user  ≥ 12 prescriptions  778 887 997 841 1.00 (0.93, 1.08) 0.93 0.91 (0.84, 0.99) 0.02 1.04 (0.97, 1.11) 0.29 0.92 (0.85, 1.00) 0.04 
             
Statin user 1 to 365 ddds  1,737 1,981 2,235 2,110 0.94 (0.89, 0.99) 0.02 0.88 (0.83, 0.93) <0.001 0.97 (0.93, 1.02) 0.27 0.89 (0.84, 0.95) <0.001 
Statin user  ≥ 365 ddds  821 917 1,052 967 0.94 (0.87, 1.01) 0.08 0.89 (0.82, 0.96) 0.004 0.95 (0.89, 1.02) 0.14 0.88 (0.82, 0.95) 0.002 
             
Simvastatin non-user  8,977 9,966 11,265 10,499  1.00   1.00    1.00  1.00  
Simvastatin user  1,645 1,858 2,133 2,008 0.95 (0.90, 1.00) 0.05 0.92 (0.86, 0.97) 0.004 0.97 (0.92, 1.02) 0.18 0.92 (0.87, 0.97) 0.003 
             
Atorvastatin non-user  9,832 10,922 12,392 11,549  1.00   1.00    1.00  1.00  
Atorvastatin user 790 902 1,006 958 0.93 (0.87, 1.00) 0.06 0.91 (0.85, 0.99) 0.02 0.96 (0.90, 1.03) 0.28 0.93 (0.87, 1.00) 0.05 
             
Pravastatin non-user  10,468 11,643 13,200 12,332  1.00   1.00    1.00  1.00  
Pravastatin user  154 181 198 174 0.99 (0.84, 1.16) 0.88 0.96 (0.82, 1.12) 0.60 1.05 (0.90, 1.21) 0.54 1.00 (0.86, 1.16) 0.96 
             
Rosuvastatin non-user 10,555 11,750 13,310 12,418  1.00   1.00    1.00  1.00  
Rosuvastatin user 67 74 88 89 0.83 (0.66, 1.06) 0.14 0.82 (0.65, 1.05) 0.11 0.83 (0.66, 1.05) 0.12 0.81 (0.64, 1.02) 0.07 
             
Fluvastatin non-user 10,575 11,771 13,341 12,464  1.00   1.00    1.00  1.00  
Fluvastatin user  47 53 57 43 1.03 (0.78, 1.38) 0.82 1.01 (0.76, 1.35) 0.93 1.06 (0.81, 1.39) 0.68 1.03 (0.78, 1.35) 0.85 
             
Any lipophilicb non-user 8,922 9,904 11,200 10,455  1.00   1.00    1.00  1.00  
Any lipophilic statin user  1,700 1,920 2,198 2,052 0.95 (0.91, 1.00) 0.07 0.92 (0.87, 0.98) 0.01 0.97 (0.93, 1.02) 0.25 0.92 (0.87, 0.98) 0.01 
             
Any hydrophilicb non-user 9,631 10,690 12,129 11,302  1,00   1.00    1,00  1.00  
Any hydrophilic statin user  991 1,134 1,269 1,205 0.93 (0.87, 0.99) 0.02 0.90 (0.84, 0.96) 0.003 0.96 (0.90, 1.02) 0.17 0.92 (0.86, 0.98) 0.01 
a Adjusted for year of diagnosis, age at diagnosis, gender, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial 
infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (in year prior to diagnosis, specifically low dose aspirin and beta-blockers) and deprivation (in fifths). 
b Lipohphilic statins include simvastatin, fluvastatin, cerivastatin; hydrophilic statins include atorvastatin, pravastatin and rosuvastatin. 
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Table 5. Sensitivity analyses for association between statin use and cancer-specific mortality in lung cancer patients. 
 
Cancer-
specific 
mortality
All 
patients 
Person 
years 
Unadjusted 
HR (95% CI) P 
Adjusteda  
HR (95% CI) P 
Main analysis: Pre-diagnostic statin use b  10,622 13,398 12,507 0.94 (0.90, 0.98) 0.007 0.88 (0.83, 0.93) <0.001 
Subgroup analyses        
  Male 6,292 7,918 7,115 0.91 (0.86, 0.96) 0.001 0.87 (0.80, 0.93) <0.001 
  Female 4,330 5,480 5,391 0.99 (0.92, 1.06) 0.80 0.91 (0.83, 0.99) 0.02 
Sensitivity analyses        
  Smoking prior to diagnosis available (and adjusted for) 9,519 9,519 11,329 0.96 (0.92, 1.00) 0.07 0.89 (0.84, 0.95) <0.001 
  BMI prior to diagnosis available (and adjusted for) 7,959 10,040 9,783 0.98 (0.93, 1.03) 0.42 0.92 (0.87, 0.98) 0.01 
  Additionally adjusting for bisphosphonate usec 10,622 13,398 12,507 0.94 (0.90, 0.98) 0.007 0.88 (0.83, 0.93) <0.001 
  Statin use between 2 years and 6 months prior to diagnosis d 9,733 12,260 11,437 0.93 (0.89, 0.98) 0.01 0.87 (0.82, 0.92) <0.001 
a Except where otherwise stated, adjusted for year of diagnosis, age at diagnosis, gender, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart 
disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (in year prior to diagnosis, specifically low dose aspirin and beta-blockers) 
and deprivation (in fifths). 
b Based upon use in the year prior to diagnosis, restricted to individuals with 1 year of records prior to lung cancer diagnosis. 
c Contains all confounders in a  along with bisphosphonate use in year prior to diagnosis.  
d Restricted to individuals with 2 years of records prior to diagnosis, removing prescriptions in the 6 months prior to lung cancer diagnosis as these could reflect increased medical care due to early 
symptoms.  
 
